COGNITION THERAPEUTICS CO-FOUNDER AND CSO SUSAN CATALANO TO PRESENT AT THE ANNUAL ASENT MEETING

Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Dr. Susan Catalano, Cognition’s co-founder and chief science officer, will make an oral presentation at the annual meeting of the American Society of Experimental Neurotherapeutics (ASENT) on March 8, 2018. Dr. Catalano will present results from the Elayta™ Phase 1b/2a clinical study in mild-to-moderate Alzheimer’s disease patients demonstrating Elayta’s (CT1812) unique synaptoprotective mechanism of action.

View here: https://stockguru.com/2018/03/06/cognition-therapeutics-co-founder-and-cso-susan-catalano-to-present-at-the-annual-asent-meeting/